ArticleCancers2026
Efficacy and Safety of CAR-T Cell Therapy and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma with Renal Impairment: A Propensity Score-Matched Analysis.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesT-cell-redirecting immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAbs), have transformed the treatment of relapsed/refractory multiple myeloma (RRMM). However, pivotal registration trials routinely excluded patients with significant renal impairment (RI), creating a critical evidence gap in a population where kidney disease affects 20-50% of patients at diagnosis. Direct comparisons of outcomes across the estimated glomerular filtration rate (eGFR) spectrum for both modalities are lacking.
methodsWe conducted a retrospective cohort study using the TriNetX Global Collaborative Network, a federated electronic health record research platform. Adult patients with RRMM treated with CAR-T therapy (idecabtagene vicleucel or ciltacabtagene autoleucel) or BsAbs (teclistamab, elranatamab, or talquetamab) were stratified by baseline renal function: severe RI (eGFR <30 mL/min/1.73 m
resultsA total of 2716 CAR-T and 3376 BsAb recipients were identified. After matching, 281 pairs (severe RI vs. preserved) and 878 pairs (moderate RI vs. preserved) were analyzed in the CAR-T cohort; 645 and 1158 pairs, respectively, were analyzed in the BsAb cohort. Neither severe nor moderate RI was significantly associated with increased mortality or shorter TTNT after either CAR-T or BsAb therapy. However, patients with RI experienced significantly higher rates of anemia, thrombocytopenia, and acute kidney injury (AKI) across both modalities. Cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and neutropenia rates were comparable across renal strata. In the BsAb cohort, infections were transiently elevated at 1 month in the severe RI group (RR 1.29; 95% CI 1.06-1.58;
conclusionsIn this retrospective analysis, renal impairment was not associated with inferior survival outcomes following CAR-T therapy or BsAb treatment in RRMM, suggesting that RI alone should not preclude the use of these agents. However, RI conferred increased hematologic toxicity and AKI risk, warranting enhanced supportive care and monitoring. These findings support broadening access to T-cell-redirecting immunotherapies for patients with RI with appropriate surveillance, though prospective validation is needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.